Benzinga | Nov 2, 2021 10:47AM EDT

Sage Therapeutics Q3 EPS $(2.21) Misses $(1.85) Estimate, Sales $1.44M Miss $1.96M Estimate

Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(2.21) per share which missed the analyst consensus estimate of $(1.85) by 19.46 percent. This is a 8.87 percent decrease over losses of $(2.03) per share from the same period last year. The company reported quarterly sales of $1.44 million which missed the analyst consensus estimate of $1.96 million by 26.53 percent. This is a 12.14 percent decrease over sales of $1.64 million the same period last year.